Euro Biotechnology

AK Steel Holding Corporation (NYSE:AKS) is simply too cheap to pass with a price-to-sales ratio of 0.24. The competitors from AK Steel Holding …

New immunotherapy approaches to cancer treatment, and the CRISPR technology for editing genetic material in cells, are among the most sophisticated research strategies scientists are using in their quest to defeat disease.

But as researchers develop these techniques based on manipulating biological molecules, they may still be recording their experimental results by a method untouched by technological advances-–in a paper lab notebook.

That’s the anomaly Sajith Wickramasekara was trying to correct in 2012 when he and fellow software engineer Ashu Singhal co-founded the online lab notebook startup Benchling, where he is CEO. Existing data management systems weren’t tailored for work… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-AG-2017Pillar: REC Programme 2014-2020Opening Date: Deadline: Tue, 7 Nov 2017 17:00:00 (Brussels local time)Modification Date: Thu, 14 Jun 2018Latest information: Acall update flash infodocument with the call results has been added under Topic conditions, Additional documents.

During today’s Senate Judiciary hearing, Senator Orrin Hatch addressed the dysfunctional interplay of the inter partes review system with the well-established Hatch-Waxman patent review process.

BIO shares Senator Hatch’s view that the unintended consequences created by the America Invents Act add unproductive litigation pressure on innovators and disrupt the balanced procedures that have historically made the Hatch-Waxman Act a success.

Read the full remarks, as prepared for delivery

Jayson Dallas has been appointed CEO of food allergy therapy developer Aimmune Therapeutics. Before joining Brisbane, CA-based Aimmune, Dallas was the chief commercial officer of Ultragenyx (NASDAQ: RARE) in Novato, CA. Dallas succeeds Stephen Dilly, who last year announced his plans to retire from Aimmune. The company says Dilly will continue to serve as an advisor through the end of the year. Aimmune is preparing to file for FDA approval of AR101, the company’s experimental immunotherapy for peanut allergy.

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

[Source: Research & Innovation] EU-funded research is exploring how meditation training and other preventive programmes can help Europe’s ageing society stay mentally active and physically healthy for longer. The findings can help shape a variety of programmes and policies.

BIO and BIO’s Board-level Workforce Development, Diversity and Inclusion (WDDI) Committee were disappointed that the planners of this year’s “Party at BIO – Not Associated with BIO” (PABNAB) included inappropriate entertainment. That decision does not reflect the values of this industry, BIO or the event’s sponsors.  At a time when our industry and BIO are determined to come together to embrace equality, confront unconscious bias, and condemn sexist attitudes, this event – which is independent of BIO – showed lack of awareness and sensitivity.

Since President Trump announced his plan last month to lower prescription drug prices, a lot of rumors have been flying around that cuts are coming from certain companies, such as those that make insulin for diabetes patients. Those rumors haven’t materialized into anything real yet, but they did heighten the anticipation for today’s testimony from Health and Human Services (HHS) Secretary Alex Azar (pictured) before the Senate Health committee.

Unfortunately, any additional details from Trump’s “blueprint” to cut prices remained scant. Most of Azar’s testimony on Tuesday was spent explaining and defending the blueprint, which put forward a few… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS

[Source: Research & Innovation] The prize, run as part of the European Innovation Council (EIC) pilot funded under Horizon 2020, the EU’s research and innovation programme, will award €10 million to an innovative, commercially viable and low-cost solution to launch light satellites.

An experimental Allergan pill meant to help reduce the frequency of migraines met the main goals of a key study, bolstering its chances of eventually being in the mix with a new wave of injectable migraine-preventing therapies.

The results announced Monday for the Allergan (NYSE: AGN) drug, atogepant, come a month after Amgen (NASDAQ: AMGN) won FDA approval of erenumab (Aimovig), the first marketed drug in this new class of migraine treatments. But Allergan’s results are particularly notable because atogepant is a pill. Amgen’s migraine drug, and several others still awaiting an FDA decision, are administered with a… Read more »

Reprints | Share:  

 
 
 
 

UNDERWRITERS AND PARTNERS